Nomifensine vs. imipramine
in depressed inpatients
by
Fann WE, Lyle FA, Higginbotham W
J Clin Psychiatry 1984 Apr; 45(4 Pt 2):60-2

ABSTRACT

In a double-blind random assignment study, nomifensine was compared to imipramine in a population of depressed male inpatients (N = 36; ages 22-56 years). Nomifensine and imipramine in doses of 100-150 mg/day were found to be comparable over the 4-week treatment period on the Hamilton Depression Rating Scale and Clinical Global Impressions. The Self-Rating Symptom Scale showed differences favoring nomifensine for the Depression factor at Days 3, 7, and 10. In extensive laboratory analyses, no clinically important changes were seen within or between groups. Although differences were not significant, more discomforting side effects--specifically, anticholinergic, nervousness/restlessness, and sedation--were seen in the imipramine than the nomifensine group. These results indicate that nomifensine compares favorably with imipramine in the treatment of depressed inpatients.

TCAs
Amineptine
Nomifensine
Comparative study
Retarded depression
Antidepressant toxicity
Imipramine versus amineptine
Nomifensine versus imipramine

Refs
HOME
HedWeb
Future Opioids
BLTC Research
Paradise-Engineering
Utopian Pharmacology
The Hedonistic Imperative

The Good Drug Guide
The Responsible Parent's Guide To
Healthy Mood Boosters For All The Family